BTIG analyst Marie Thibault reiterated a Buy rating on Viewray (VRAY – Research Report) yesterday and set a price target of $7.00. The company’s shares closed yesterday at $4.40.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Thibault is a 4-star analyst with an average return of 5.0% and a 35.09% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Masimo, Viewray, and Irhythm Technologies.
Currently, the analyst consensus on Viewray is a Strong Buy with an average price target of $6.13, representing a 39.32% upside. In a report released on October 23, Piper Sandler also maintained a Buy rating on the stock with a $6.00 price target.
See the top stocks recommended by analysts >>
Based on Viewray’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $22.15 million and a GAAP net loss of $27.63 million. In comparison, last year the company earned a revenue of $15.03 million and had a GAAP net loss of $30.98 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ViewRay, Inc. engages in the design, manufacture and market magnetic resonance imaging (MRI) system. It develops MRIdian to address the key limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery. The company was founded by Dinara Akzhigitova on September 6, 2013 and is headquartered in Oakwood Village, OH.
Read More on VRAY:
- Abstracts show superior outcomes provided by MRIdian, says Piper Sandler
- ViewRay launches LAP-ABLATE study
- ViewRay seeing order book momentum into year-end, says Piper Sandler
- ViewRay management to meet virtually with Piper Sandler
- ViewRay announces MD Anderson Cancer Center purchase of MRIdian therapy system